logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Pharmaceutical Intermediates > High Purity BIAPENEM SIDE CHAIN CAS 153851-71-9

High Purity BIAPENEM SIDE CHAIN CAS 153851-71-9

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 153851-71-9

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,T/T,D/P,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

BIAPENEM SIDE CHAIN

,

CAS 153851-71-9 BIAPENEM SIDE CHAIN

CAS NO::
153851-71-9
Appearance::
White Or Off-white Powder
Molecular Formula::
C5H8ClN3S
Molecular Weight::
177.65500
EINECS NO::
604-929-8
MDL NO::
MFCD08062366
CAS NO::
153851-71-9
Appearance::
White Or Off-white Powder
Molecular Formula::
C5H8ClN3S
Molecular Weight::
177.65500
EINECS NO::
604-929-8
MDL NO::
MFCD08062366
High Purity BIAPENEM SIDE CHAIN CAS 153851-71-9

Product Description:

Product Name: BIAPENEM SIDE CHAIN CAS NO: 153851-71-9


Synonyms:

6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-thiol,chloride;

6,7-dihydro-6-mercapto-5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium chloride;


Chemical & Physical Properties:

Appearance: White or off-white powder

Assay :≥99.00%

Melting Point: 127-128℃ (decomp)


Safety Information:

HS Code: 2933990090


Biapenem side chain is a pharmaceutical raw material that can be used to produce Biapenem antibiotics. Biapenem (LJC 10627) is a carbapenem antibiotic for injection developed by Japanese Lederle Company and American Cyanamid Company in 1989. It is now completed in Phase III clinical studies in Japan and waits for approval. The most significant feature of this product is that the S in 2-position has bicyclic triazole 1β-methyl carbapenem. The study of structure-activity relationship shows that the presence of the side chain quaternary ammonium cation center is the key to affect the permeability of the outer membrane, so that its ability to inhibit the activity of pseudomonas aeruginosa and anaerobic bacteria is 2~4 times that of imipenem, its ability to inhibit the activity of drug-resistant pseudomonas aeruginosa is 4 to 8 times that of Meropenem, and its effect on acinetobacter and anaerobic bacteria is more effective than ceftazidime.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.